We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Case report demonstrates sustained clinical response to reduced-dose trametinib in refractory Darier disease, suggesting a viable therapeutic alternative.
No takes yet. Share an insight, caveat, or question.
Haskel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: